Y-mAbs Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenues
Product
License
Total revenues
COST OF GOODS SOLD
License royalties
GROSS PROFIT
OPERATING COSTS AND EXPENSES
License royalties
Total operating expenses
Research and development
General and administrative
Selling, general, and administrative

Total operating costs and expenses
Loss from operations
OTHER INCOME, NET
Gain from sale of priority review voucher, net
Interest and other loss, net
Interest and other income

LOSS BEFORE INCOME TAXES
(Benefits)/provision for income taxes
NET LOSS
Other comprehensive income/(loss)
Foreign currency translation
COMPREHENSIVE LOSS
Net loss per share attributable to common stockholders, basic and diluted
Weighted average common shares outstanding, basic and diluted
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)
Weighted average common shares outstanding, basic (in shares)
Weighted average common shares outstanding, diluted (in shares)

Comments